key: cord-0950414-g21pn50j
authors: Mair, Maximilian J.; Mitterer, Manfred; Gattinger, Pia; Berger, Julia M.; Trutschnig, Wolfgang; Bathke, Arne C.; Gansterer, Margaretha; Berghoff, Anna S.; Laengle, Severin; Gottmann, Lynn; Buratti, Thomas; Haslacher, Helmuth; Lamm, Wolfgang W.; Raderer, Markus; Tobudic, Selma; Fuereder, Thorsten; Valenta, Rudolf; Fong, Dominic; Preusser, Matthias
title: Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
date: 2022-04-12
journal: Cancer Cell
DOI: 10.1016/j.ccell.2022.04.003
sha: 4c8dbcd6e22fef2e1aca626013c5100d5c69485c
doc_id: 950414
cord_uid: g21pn50j

nan

2 Patients with cancer are at high risk for severe clinical courses of COVID-19 and delays of antineoplastic treatment due to SARS-CoV-2 infections (Pinato et al., 2022) . SARS-CoV-2 vaccinations were shown to be quite effective and well-tolerated according to postauthorization data and real-life studies of hemato-oncological cohorts (Corti et al., 2022) .

However, we (Mair et al., 2022a (Mair et al., , 2022b and others have shown that antibody levels in patients with cancer are lower than in healthy controls, and specific subgroups such as patients receiving B cell-targeting treatments exhibit particularly low seroconversion rates.

With the emergence of immune-evading variants of concern (VOC) such as Delta (B.1.617) and Omicron (B.1.1.529), vaccination efficacy against symptomatic infections is considerably impaired in the general population, although protection against severe courses and hospital admission seems to be maintained (Andrews et al., 2022; Collie et al., 2022) . Also in patients with cancer, disease severity in Omicron-infected individuals appears to be lower than previous virus variants (Lee et al., 2022) . Therefore, precautionary measures are increasingly being lifted due to increasing vaccination coverage and the seemingly lower pathogenicity of the Omicron VOC in the general population. Nevertheless, mild SARS-CoV-2 infections and subsequent quarantine measures may disrupt anticancer treatment and thereby potentially impact survival prognosis in these patients. Data on the impact of VOC on vaccination efficacy and neutralizing ability of vaccination-induced antibodies, particularly the Omicron variant, are scarce in patients with different types of cancer with and without systemic treatment (Fendler et al., 2022) .

Here, we analyzed the time course of the occurrence of SARS-CoV-2 infections in a large cohort of patients with cancer managed in Austria and Italy throughout the pandemic (Supplemental information). In total, 3,959 patients were included, of whom 3,036/3,959 (76.7%) had been diagnosed with a solid tumor and 923/3,959 (23.2%) with a hematologic malignancy. Of note, 2,737/3,959 (69.1%) did not undergo systemic anti-neoplastic treatment at the time of vaccination. Between Feb 24, 2020 and database lock (Feb 28, 2022), 950/3,959 J o u r n a l P r e -p r o o f (24.0%) patients had been infected with SARS-CoV-2. Moreover, 3, 368/3, 959 (85.1%) patients had received at least one vaccination dose, whereas 588/3,959 (14.9%) were unvaccinated. Baseline characteristics are shown in Table S1 .

The weekly numbers of SARS-CoV-2 infections and COVID-associated hospitalizations according to vaccination status over time are illustrated in Figure S1A . Figure S1C ), indicating a particularly impaired vaccination-induced immunity against VOCs in patients receiving systemic antineoplastic agents.

In addition, we observed that hospital admissions were less common during the Omicron than during the Delta wave irrespective of vaccination status ( Figure S1A) . Vaccinated patients had a tendency for shorter hospital stays [median/range: 15 (1-41) days] than unvaccinated patients [median/range: 9 (1-79) days; p=0.126, Figure S1D ], suggesting a retained protection against severe COVID-19 in vaccinated individuals. In line, only 1/11 (9.1%) patients requiring intensive care unit (ICU) admission was attributable to a breakthrough infection.

To gain deeper insights underlying the higher rate of breakthrough infections due to Omicron compared to Delta, we investigated humoral immunity after SARS-CoV-2 vaccination against VOCs. In particular, we measured levels of antibodies specific for the receptor-binding domain (RBD) on the SARS-CoV-2 spike protein of VOCs and their ability to inhibit the interaction of RBD with the human angiotensin-converting enzyme 2 (ACE2) receptor in a subgroup of J o u r n a l P r e -p r o o f 4 patients with cancer undergoing antineoplastic treatment (Gattinger et al., 2022) 

In total, 78 patients (28 with solid tumors, 26 with hematologic malignancies receiving B celltargeted treatments, 24 with hematologic malignancies receiving other therapy) and 25 healthcare workers (HCW) as controls were included (Table S1). With regard to total anti-spike (S) protein IgG levels, there were significant differences between cohorts (p=0.009, Kruskal-Wallis test, Figure S2A ). Anti-S IgG levels were higher in HCW [median optical density (OD): Differences between groups were more accentuated for RBD-specific antibodies. Antibody levels to RBD of wildtype (hu-1) were lowest in patients receiving B cell-targeted agents Kruskal-Wallis test, Figure S2B ). Similar results were seen for RBD-Delta (p<0.001, Figure   S2C ) and RBD-Omicron levels (p<0.001, Figure S2D ). Multivariate non-parametric analysis for RBD levels between groups confirmed these findings (p<0.001), with significant differences (p<0.05) for each VOC-specific RBD individually. Corrected pairwise comparisons between cohorts showed significant differences (p<0.05) for each pair except between patients with hematologic malignancies without B cell-targeted treatment and patients with solid tumors. Of note, RBD-specific antibody levels numerically decreased from hu-1 to Delta and Omicron in all cohorts.

In addition, we performed molecular interaction assays to measure the inhibition of RBD-ACE2 binding by patients' sera. Most patients with solid tumors and hematologic malignancies J o u r n a l P r e -p r o o f without B cell-targeted treatment exhibited RBD-ACE2 binding of more than 50% inhibition for hu-1 (median inhibition solid tumors: 98.5%, range: 15.7%-100.6%; median hematologic malignancies: 91.8%, range: 22.7-100.6%; Figure S2E ) and Delta VOC (median inhibition solid tumors: 94.4%, range: -13.7%-100.6%; median hematologic malignancies: 59.2%, range:

-49.7%-100.8%, Figure S2F ). In contrast, patients receiving anti-B cell treatment showed considerably lower values (median inhibition hu-1: 21.7%, range: -11.0-101.4%; median inhibition Delta: 13.1%, range: -48.4%-100.9%). Of note, RBD-ACE2 binding inhibition was markedly impaired for the Omicron variant in patients with solid tumors (median inhibition:

16.6%, range: -9.5%-94.6%) as well as hematologic malignancies receiving B cell-targeting agents (median inhibition -1.07%, range: -62.6%-81.0%) or other treatments (median inhibition: 5.6%, range: -43.6%-99.2%); while HCW as controls had considerably higher values (median inhibition: 79.4%, range: -1.7%-99.8%; p<0.001, Kruskal-Wallis test, Figure S2G ) than the other groups. However, inhibition of the Omicron RBD-ACE2 interaction was considerably lower than for RBD of hu-1 and Delta. Multivariate non-parametric analysis for RBD-ACE2 interaction inhibition levels between groups confirmed these findings (p<0.001), with significant differences (p<0.05) for each VOC-specific RBD individually. Corrected pairwise comparisons between cohorts showed significant differences (p<0.05) for each pair except between patients with hematologic malignancies without B cell-targeted treatment and patients with solid tumors, as well as between both hematologic patient cohorts. Again, RBD-ACE2 binding inhibition decreased from hu-1 to Delta and Omicron within all cohorts.

Our data provide a comprehensive overview on SARS-CoV-2 infections and hospitalizations during the last Delta and Omicron waves of the pandemic in patients with different forms of cancer with and without treatment. We observed an increase of SARS-CoV-2 breakthrough infections with the occurrence of the Omicron variant as compared to the Delta wave, whereas hospital admissions decreased. However, as in the general population, our data do not allow conclusions on whether reduced hospitalization rates in patients with cancer were attributable J o u r n a l P r e -p r o o f 6 to the seemingly lower pathogenicity of the Omicron variant or increasing infection/vaccination coverage.

We found immunological evidence of highly impaired vaccine-induced neutralization of the Omicron variant but not against the wildtype hu-1 strain and the previous Delta VOC in patients with hematologic and solid cancers in comparison to HCW. Indeed, comprehensive data on the neutralizing ability of vaccination-induced antibodies against VOCs are rare in hematooncologic patients, in particular concerning the Omicron variant (Fendler et al., 2022) . While prior studies investigating prior virus variants showed impaired humoral responses mainly in the subpopulation of patients with hematologic malignancies receiving B-cell depleting therapies (Obeid et al., 2022) , our immunological data indicate virtually lacking humoral vaccine response against the most recent Omicron VOC across a much broader population of patients with cancer.

Our study has important limitations including the retrospective design which is inherently linked to heterogeneity as well as missing data. Whereas the number of received vaccinations was known in all patients, missing information on vaccination dates impeded further testing on timedependent risks for infection and hospitalization. In addition, we only measured neutralizing RBD antibody levels and their inhibitory capacity on RBD-ACE2 binding, whereas immunity against VOCs may be based also on T cell-associated immunity and other factors.

In conclusion, the increasing rates of breakthrough infections and hospital admissions of Supplemental Table S1 . Baseline characteristics of the included cohorts.

J o u r n a l P r e -p r o o f

In this retrospective observational study, we included patients with hematologic malignancies and solid tumors and, for control purposes, healthcare workers ( 

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Omicron: A SARS-CoV-2 variant of real concern

Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events -a retrospective cohort study

In Merano/Meran, serum was obtained from patients with hematologic malignancies under active antineoplastic treatment. All included patients provided informed consent prior to serum sampling. ELISA and molecular interaction assay Specific immunoglobulin levels to SARS-CoV-2 S protein hu-1, RBD-hu-1 and RBD from VOC Delta and Omicron as well as inhibition of RBD to ACE2 receptor binding by patients

Bound human IgA, IgM, or IgG1-4 were detected by incubation with either mouse anti-human IgA (BD), mouse anti-human IgM (BD), mouse anti-human IgG1 (BD), mouse anti-human IgG2 (BD), mouse anti-human IgG3 (Sigma), or mouse anti-human IgG4 (BD) (all 1:1000 diluted) followed by incubation with 1:2000 HRP-conjugated anti-mouse IgG

In brief, 1:2 diluted serum was incubated for 3 hours with 100 ng of His-tagged RBDhu-1, RBD-Delta, and RBD-Omicron (Genscript) followed by a 3-hours incubation of the mix J o u r n a l P r e -p r o o f with plate-bound ACE2 (2 µg/ml) (Genscript). Bound RBD was detected with a mouse monoclonal anti-His antibody

Detection with ABTS as substrate and measurement of the color reactions was done as described above. The percentages of inhibition were calculated as described

Testing for equal proportions was done via Fisher's exact test, while testing for equal numberof-hospitalization-day distributions was performed using the function nonpartest from the Rpackage npmv. Differences in immunoglobulin reactivity to proteins or differences of inhibition of receptor binding were determined using the Kruskal-Wallis test and a fully non-parametric inference method for multivariate data

USA) and R 4.0.2 (The R Project for Statistical Computing

How to compare small multivariate samples using nonparametric tests

Nonparametric Inference for Multivariate Data: The R Package npmv

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding

Omicron: A SARS-CoV-2 variant of real concern

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes

Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank

A nonparametric version of Wilks' lambda--Asymptotic results and small sample approximations

SARS-CoV-2-Varianten in Österreich